Stem-cell therapy for male-factor infertility aims to restore sperm production and hormonal balance. Clinical results include improved sperm concentration, motility, and testosterone levels. Approximately 22.5% of non-obstructive azoospermia patients may see sperm reappear in ejaculate 6 to 12 months after receiving autologous mesenchymal stem cells.
- Sperm parameter gains: Significant increases in count and motility often appear 6–12 months post-injection.
- Hormonal normalization: Treatment frequently increases testosterone and Inhibin B while lowering FSH and LH.
- Regenerative potential: Therapy stimulates seminiferous tubule repair to restore the testicular microenvironmental niche.
- Sexual function: Many patients report improved libido and erectile function following regenerative protocols.
Bookimed Expert Insight: Turkish clinics like Valued Med Hub Hospitals leverage urologists trained at the Cleveland Clinic to combine autologous harvesting with growth-factor support. While the US average cost is $22,500, Turkey offers these advanced protocols from $4,500, saving patients up to 71%. This price gap allows patients to budget for required IVF or ICSI backup cycles.
Patient Consensus: Patients report manageable 1-day procedures but emphasize managing expectations regarding natural conception. Most see modest 10–30% semen analysis gains and recommend verifying if clinics offer peer-reviewed pregnancy data before booking.